Maria Antônia Costa Cruz Akabane

Maria Antônia Costa Cruz Akabane

Auto-generated profile, based on publicly available information

Maria Antônia Costa Cruz Akabane

Faculty of Medicine, Federal University of Juiz de Fora, Juiz de Fora, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2026 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
ALAyomide Lawal
Ayomide Lawal
ARAmanda Ribeiro Rangel
Amanda Ribeiro Rangel
ARAdvait Raja
Advait Raja
MAMaria Antônia Costa Cruz Akabane
Maria Antônia Costa Cruz Akabane
NLNathália Veloso Lana
Nathália Veloso Lana
KHKelen Klein Heffel
Kelen Klein Heffel

18 October 2025 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
AVAna Carolina Putini Vieira
Ana Carolina Putini Vieira
MAMaria Antônia Costa Cruz Akabane
Maria Antônia Costa Cruz Akabane
GCGianna Carolinne Graff Caletti
Gianna Carolinne Graff Caletti
KHKélen Klein Heffel
Kélen Klein Heffel
ASAmanda Tauana Oliveira e Silva
Amanda Tauana Oliveira e Silva
Prurigo nodularis (PN) is a chronic, debilitating inflammatory skin disorder characterized by persistent itching, firm pruritic nodular lesions, and evidence of frequent scratching, like excoriation, and lichenification. Nemolizumab, a monoclonal antibody targeting IL-31, has shown significant improvements in skin lesions, itching, and sleep disturbances by reducing type 2 immune responses in PN. Evaluate the efficacy and safety of nemolizumab in treating PN by systematically analyzing randomized controlled trials (RCTs). The authors conducted a systematic review and meta-analysis by searching Pubmed, Embase, Cochrane Central and Scopus for RCTs comparing nemolizumab to placebo for PN. Statistical analysis usedR Studio 4.3.2. Three trials, involving 630 patients, were included. Nemolizumab significantly reduced pruritus at week-4 (MD = -32.04; 95% CI: -38.47, -25.62) and at week-16 (MD = -347.34; 95% CI: -1039.71, 345.04). Investigator's Global Assessment (IGA) success favored Nemolizumab at week-16 (RR = 3.50; 95% CI: 2.18, 5.63). No significant differences were observed in adverse events (RR = 1.10; 95% CI: 0.97, 1.25) or serious adverse events (RR = 0.77; 95% CI: 0.43, 1.39). Nemolizumab also significantly reduced neurodermatitis. Limitations include variability in treatment duration, small sample sizes, and the lack of direct comparisons with other biologics. Our meta-analysis shows that Nemolizumab significantly improves pruritus, IGA success rates, and PAS > 75% in treating patients with moderate to severe PN. Its safety profile is favorable, with no significant differences in adverse events compared to placebo. These findings support Nemolizumab as a viable treatment for moderate to severe PN.

31 October 2025 in Anais Brasileiros de Dermatologia (Versão em Português)
Verified
Journal Article
Open access
AVAna Carolina Putini Vieira
Ana Carolina Putini Vieira
MAMaria Antônia Costa Cruz Akabane
Maria Antônia Costa Cruz Akabane
GCGianna Carolinne Graff Caletti
Gianna Carolinne Graff Caletti
KHKélen Klein Heffel
Kélen Klein Heffel
ASAmanda Tauana Oliveira e Silva
Amanda Tauana Oliveira e Silva